KR20230116097A - 호흡기 세포 융합 바이러스 감염의 치료 및 예방을위한 스피로-인돌린 - Google Patents

호흡기 세포 융합 바이러스 감염의 치료 및 예방을위한 스피로-인돌린 Download PDF

Info

Publication number
KR20230116097A
KR20230116097A KR1020237025697A KR20237025697A KR20230116097A KR 20230116097 A KR20230116097 A KR 20230116097A KR 1020237025697 A KR1020237025697 A KR 1020237025697A KR 20237025697 A KR20237025697 A KR 20237025697A KR 20230116097 A KR20230116097 A KR 20230116097A
Authority
KR
South Korea
Prior art keywords
substituted
alkyl
groups
membered
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237025697A
Other languages
English (en)
Korean (ko)
Inventor
스튜어트 코커릴
닐 매슈스
사이먼 워드
그레이엄 룬
마이클 파라도프스키
시모트 호세 미겔 가스콘
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51946966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20230116097(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20230116097A publication Critical patent/KR20230116097A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237025697A 2014-10-07 2015-10-06 호흡기 세포 융합 바이러스 감염의 치료 및 예방을위한 스피로-인돌린 Pending KR20230116097A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1417707.5 2014-10-07
GBGB1417707.5A GB201417707D0 (en) 2014-10-07 2014-10-07 Pharmaceutical compounds
KR1020177012311A KR102561796B1 (ko) 2014-10-07 2015-10-06 호흡기 세포 융합 바이러스 감염의 치료 및 예방을 위한 스피로-인돌린
PCT/GB2015/052920 WO2016055780A1 (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012311A Division KR102561796B1 (ko) 2014-10-07 2015-10-06 호흡기 세포 융합 바이러스 감염의 치료 및 예방을 위한 스피로-인돌린

Publications (1)

Publication Number Publication Date
KR20230116097A true KR20230116097A (ko) 2023-08-03

Family

ID=51946966

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237025697A Pending KR20230116097A (ko) 2014-10-07 2015-10-06 호흡기 세포 융합 바이러스 감염의 치료 및 예방을위한 스피로-인돌린
KR1020177012311A Active KR102561796B1 (ko) 2014-10-07 2015-10-06 호흡기 세포 융합 바이러스 감염의 치료 및 예방을 위한 스피로-인돌린

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177012311A Active KR102561796B1 (ko) 2014-10-07 2015-10-06 호흡기 세포 융합 바이러스 감염의 치료 및 예방을 위한 스피로-인돌린

Country Status (31)

Country Link
US (1) US10106539B2 (cg-RX-API-DMAC10.html)
EP (1) EP3204375B1 (cg-RX-API-DMAC10.html)
JP (1) JP6695334B2 (cg-RX-API-DMAC10.html)
KR (2) KR20230116097A (cg-RX-API-DMAC10.html)
CN (1) CN107108557B (cg-RX-API-DMAC10.html)
AR (1) AR102181A1 (cg-RX-API-DMAC10.html)
AU (1) AU2015329778B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017007311B1 (cg-RX-API-DMAC10.html)
CA (1) CA2963740C (cg-RX-API-DMAC10.html)
CL (1) CL2017000839A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017004603A2 (cg-RX-API-DMAC10.html)
CY (1) CY1121564T1 (cg-RX-API-DMAC10.html)
DK (1) DK3204375T3 (cg-RX-API-DMAC10.html)
ES (1) ES2718976T3 (cg-RX-API-DMAC10.html)
GB (1) GB201417707D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20190808T1 (cg-RX-API-DMAC10.html)
HU (1) HUE043553T2 (cg-RX-API-DMAC10.html)
LT (1) LT3204375T (cg-RX-API-DMAC10.html)
MX (1) MX373233B (cg-RX-API-DMAC10.html)
NZ (1) NZ731323A (cg-RX-API-DMAC10.html)
PE (1) PE20170949A1 (cg-RX-API-DMAC10.html)
PL (1) PL3204375T3 (cg-RX-API-DMAC10.html)
PT (1) PT3204375T (cg-RX-API-DMAC10.html)
RS (1) RS58706B1 (cg-RX-API-DMAC10.html)
RU (1) RU2734248C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201702766YA (cg-RX-API-DMAC10.html)
SI (1) SI3204375T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201900249T1 (cg-RX-API-DMAC10.html)
TR (1) TR201903362T4 (cg-RX-API-DMAC10.html)
TW (1) TWI718107B (cg-RX-API-DMAC10.html)
WO (1) WO2016055780A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197908A1 (zh) * 2015-06-08 2016-12-15 南京明德新药研发股份有限公司 咪唑衍生物及其中间体的制备方法和晶型
WO2018025043A1 (en) 2016-08-04 2018-02-08 ReViral Limited Pyrimidine derivatives and their use in treating or preventing a respiratory syncytial virus infection
GB201711704D0 (en) * 2017-07-20 2017-09-06 Reviral Ltd Pharmaceutical compounds
GB201721812D0 (en) * 2017-12-22 2018-02-07 Reviral Ltd Pharmaceutical compounds
CN116077494A (zh) * 2023-01-11 2023-05-09 黑龙江中医药大学 一种治疗呼吸道合胞病毒的药物组合物及其制备方法
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
CN122580320A (zh) 2024-01-16 2026-08-14 辉瑞大药厂 作为n-蛋白抑制剂的苯二氮䓬吡唑甲酰胺类
WO2025248535A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel spirocyclic compounds to treat viral infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57102863A (en) * 1980-12-16 1982-06-26 Takeda Chem Ind Ltd Spiroindolinone and its preparation
RU2184735C2 (ru) * 1998-01-23 2002-07-10 Санкио Компани, Лимитед Производные спиропиперидина, лекарственное средство, способ профилактики или лечения
EP1418175A1 (en) * 1999-06-28 2004-05-12 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
US7205328B2 (en) * 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
EP1802637B1 (en) 2004-10-13 2008-10-15 Merck & Co., Inc. Cgrp receptor antagonists
US20100278835A1 (en) 2009-03-10 2010-11-04 Astrazeneca Uk Limited Novel compounds 660
GB201119538D0 (en) * 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
AU2013334001B2 (en) 2012-10-16 2017-07-20 Janssen Sciences Ireland Uc RSV antiviral compounds
KR20160007629A (ko) * 2013-05-14 2016-01-20 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
JP2016518421A (ja) * 2013-05-14 2016-06-23 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール
MX2016001855A (es) * 2013-08-12 2016-05-24 Hoffmann La Roche Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
KR20160030271A (ko) * 2013-08-12 2016-03-16 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
HK1222855A1 (zh) 2013-08-15 2017-07-14 F. Hoffmann-La Roche Ag 新的用於治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚
KR20160030569A (ko) * 2013-08-15 2016-03-18 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 아자-옥소-인돌

Also Published As

Publication number Publication date
AU2015329778A1 (en) 2017-05-04
MX2017004425A (es) 2017-10-11
HRP20190808T1 (hr) 2019-08-23
CA2963740A1 (en) 2016-04-14
JP2017530992A (ja) 2017-10-19
RU2017113026A (ru) 2018-11-13
NZ731323A (en) 2022-09-30
CN107108557B (zh) 2020-11-10
PE20170949A1 (es) 2017-07-13
GB201417707D0 (en) 2014-11-19
HUE043553T2 (hu) 2019-09-30
CN107108557A (zh) 2017-08-29
BR112017007311B1 (pt) 2022-11-22
DK3204375T3 (en) 2019-04-01
ES2718976T3 (es) 2019-07-05
TR201903362T4 (tr) 2019-04-22
MX373233B (es) 2020-05-08
CY1121564T1 (el) 2020-05-29
KR102561796B1 (ko) 2023-07-31
CL2017000839A1 (es) 2017-10-13
PT3204375T (pt) 2019-04-01
SMT201900249T1 (it) 2019-07-11
CO2017004603A2 (es) 2017-10-31
US20170305908A1 (en) 2017-10-26
KR20170066577A (ko) 2017-06-14
LT3204375T (lt) 2019-05-10
WO2016055780A1 (en) 2016-04-14
AU2015329778B2 (en) 2020-04-23
RU2734248C2 (ru) 2020-10-13
RU2017113026A3 (cg-RX-API-DMAC10.html) 2019-03-22
EP3204375B1 (en) 2019-02-13
US10106539B2 (en) 2018-10-23
PL3204375T3 (pl) 2019-06-28
CA2963740C (en) 2022-11-29
EP3204375A1 (en) 2017-08-16
AR102181A1 (es) 2017-02-08
TWI718107B (zh) 2021-02-11
AU2015329778A8 (en) 2017-05-18
RS58706B1 (sr) 2019-06-28
TW201625583A (zh) 2016-07-16
BR112017007311A2 (pt) 2017-12-19
JP6695334B2 (ja) 2020-05-20
SG11201702766YA (en) 2017-05-30
SI3204375T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
KR102561796B1 (ko) 호흡기 세포 융합 바이러스 감염의 치료 및 예방을 위한 스피로-인돌린
KR101996335B1 (ko) 약제학적 화합물
EP3204388B1 (en) Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivatives
US10626126B2 (en) Compounds
EP3033341B1 (en) Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
KR20140025321A (ko) 벤즈이미다졸 호흡기 세포융합 바이러스 억제제
CN114761397B (zh) 用于治疗呼吸道合胞病毒(rsv)感染的苯并二氮䓬衍生物
CN114787155B (zh) 药物化合物
AU2014209853A1 (en) Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents
WO2022008911A1 (en) Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection
KR20170094180A (ko) 호흡기 세포융합 바이러스 (rsv)의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 삼환식 피라졸로[1,5―a]피리미딘 유도체
WO2018025043A1 (en) Pyrimidine derivatives and their use in treating or preventing a respiratory syncytial virus infection

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230726

Application number text: 1020177012311

Filing date: 20170504

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240412

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250123